Target intelligence / Profile preview

Histone H3 and Histone H4 (H3 and H4)

Target
H3 and H4
Molecular classification
Histone protein, Chromatin structural protein, Epigenetic regulator
01

Overview

Histone H3 and Histone H4 are highly conserved nuclear proteins fundamental to eukaryotic chromatin structure. Together with histones H2A and H2B, they form the nucleosome core around which DNA is wrapped, enabling efficient DNA packaging and contributing to chromatin architecture. Both H3 and H4 possess N-terminal tails that undergo extensive post-translational modifications—including acetylation, methylation, phosphorylation, and ubiquitination—that regulate gene transcription, DNA replication, DNA repair, and chromosome stability by altering chromatin accessibility. These modifications serve as “epigenetic marks” linked to cellular differentiation, development, and disease processes. Dysregulation or mutation of histone H3 or H4 or their modifying enzymes is implicated in various cancers, developmental syndromes, and neurodegenerative diseases. Targeting histone-modifying processes is an established therapeutic strategy, with several approved drugs that act as inhibitors of histone deacetylases and methyltransferases, affecting the function of H3 and H4 within the chromatin context[2][4][5][6][8].

Other names
Core histones H3 and H4H3 histone familyH4 histone familyHistone cluster proteins (various gene-based aliases: HIST1H4A, HIST1H3A, etc.)
02

Mechanism of action

Inhibition of histone deacetylation (leads to increased acetylation and gene expression) Inhibition of histone methylation (impacts chromatin state and transcription) Modulation of nucleosome dynamics and chromatin accessibility

03

Biological functions

DNA packaging in nucleosomesRegulation of gene transcriptionDNA replicationDNA repairMaintenance of genome stability
04

Disease associations

CancerNeurodegenerative diseasePremature aging syndromes (e.g., progeria)Other cell cycle and developmental disorders
05

Safety considerations

Broad effects on gene expression with risk of off-target toxicityMutagenesis and genomic instability with chromatin-modifying drugsPotential for dysregulation of cell cycle and apoptosis in normal cells
06

Interacting drugs

Histone deacetylase inhibitors (e.g., vorinostat, romidepsin)

3 more in the full profile.

07

Biomarkers

Histone modification states (e.g., H3K27ac, H4K16ac for transcriptionally active chromatin)Global levels or specific patterns of histone acetylation/methylation

Beyond the preview

Go deeper on Histone H3 and Histone H4 (H3 and H4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone H3 and Histone H4 (H3 and H4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call